Catastrophic Health Expenditure and Health‐Related Quality of Life Impairment in Severe Haemophilia A: A Patient‐Level Cost‐of‐Illness Study From India
Haemophilia · 2026-11 · 32 (6) · 1444-1454
DOI: 10.1111/hae.70323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 04.06.2026. Verfasst von M Joseph John und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Haemato-Oncology & Bone Marrow (Stem Cell) Transplantation, Christian Medical College, Ludhiana, Punjab, India. Hauptthemen laut MEDLINE: Hemophilia A, Quality of Life, Health Expenditures, Cost of Illness. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Takeda Pharmaceuticals India Pvt. Ltd..
Abstract (Originalsprache)
Introduction
Severe haemophilia A (sHA) is associated with disability, and financial burden. Even with government provided or humanitarian‐aid‐supported on‐demand therapy, households may remain vulnerable to catastrophic health expenditure (CHE).
Aim
To estimate the patient‐level costs and economic burden of sHA and to assess CHE under multiple thresholds.
Methods
In this cross‐sectional study, costs were estimated from a patient/household perspective. Clotting‐factor concentrate (CFC) costs were excluded from the base case because factor VIII was provided free through government and/or humanitarian‐aid‐supported mechanisms. Costs were standardized to 2025 Indian Rupees using Consumer Price Index (CPI) adjustments (US$ (₹90 = US$1)). CHE was assessed at 10% and 25% of total household expenditure and 40% of household capacity to pay.
Results
The median annual patient‐level cost per patient, excluding CFCs, was ₹73,919 (US$821). CHE occurred in 63% of households at the 10% threshold and in 44% at the 40% capacity‐to‐pay threshold. Distance > 50 km From the treatment centre (aOR 6.62) and hospitalization history (aOR 10.60) were associated With CHE. Median cost per bleeding episode, excluding factor costs, was ₹4,468 (US$50; IQR ₹8,311 [US$92]). HRQoL utilities were modestly reduced and weakly correlated With costs, suggesting a financial–disability utility paradox. Sensitivity analysis identified clotting‐factor price as the dominant cost driver Conclusion SHA imposes substantial financial burden Despite free factor provision. Reliance on on‐demand therapy may contribute to recurrent bleeding, hospitalizations, and CHE, whereas long‐term replacement strategies may reduce complications and financial toxicity. Prospective comparative studies are needed in resource‐constrained settings Clinical Trial Registration This study was not a clinical trial and, therefore, did not require clinical trial registration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Haematology, Haemato-Oncology & Bone Marrow (Stem Cell) Transplantation, Christian Medical College, Ludhiana, Punjab, India.
- Department of Community Medicine & School of Public Health, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Förderung
- Takeda Pharmaceuticals India Pvt. Ltd.
Zitieren
APA
John, M. J., Makkar, M., Aggarwal, H., Singh, D., Ohja, S., Sarwan, D., Jyani, G., & Prinja, S. (2026). Catastrophic Health Expenditure and Health‐Related Quality of Life Impairment in Severe Haemophilia A: A Patient‐Level Cost‐of‐Illness Study From India. Haemophilia, 32(6), 1444-1454. https://doi.org/10.1111/hae.70323
Vancouver
John MJ, Makkar M, Aggarwal H, Singh D, Ohja S, Sarwan D, et al. Catastrophic Health Expenditure and Health‐Related Quality of Life Impairment in Severe Haemophilia A: A Patient‐Level Cost‐of‐Illness Study From India. Haemophilia. 2026;32(6):1444-1454. doi:10.1111/hae.70323
BibTeX
@article{John2026,
author = {John, M Joseph and Makkar, Mridul and Aggarwal, Himanshu and Singh, Damanpreet and Ohja, Soumya and Sarwan, Diksha and Jyani, Gaurav and Prinja, Shankar},
title = {Catastrophic Health Expenditure and Health‐Related Quality of Life Impairment in Severe Haemophilia A: A Patient‐Level Cost‐of‐Illness Study From India},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {6},
pages = {1444--1454},
doi = {10.1111/hae.70323}
}
EUVIMED